Microvessel density in ovarian carcinoma: Computer image analysis in patients with shorter and longer survival

International Journal of Gynecological Cancer

Volumn 15, Issue 5, 2005, Pages 844-849

  Raspollini, Maria Rosaria ^a   Amunni, G ^a   Villanucci, A ^a   Baroni, G ^a   Boddi, V ^a   Degl'Innocenti, D Rossi ^a   Taddei, G L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Angiogenesis; CD34; Computer image analysis; MVD; Ovarian carcinoma; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER AIDED DESIGN; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MICROVASCULATURE; OVARY CARCINOMA; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

AGE FACTORS; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 28944440343     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00146.x     Document Type: Article

References (24)

1. DiSaia PJ, Bloss JD. Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003;14:S24-32.
2. Joensuu H, Robert PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.
3. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1:11-21.
4. Rodriguez-Burford C, Barnes MN, Oelschlager DK et al. Effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 2002;8:202-9.
5. Raspollini MR, Amunni G, Villanucci A et al. Prognostic significance of microvessel density (MVD) and vascular endothelial growth factor (VEGF) expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 2004;14:815-23.
6. Brower V. Tumor angiogenesis - new drugs on the block. Nat Biotechnol 1999;17:963-8.
7. Giavazzi R, Taraboletti G. Angiogenesis and angiogenesis inhibitors in cancer. Forum 1999;9:261-72.
8. Taraboletti G, Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol 2001;1:378-84.
9. Weider N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
10. De Vita VT, Hellman S, Rosemberg SA. Cancer: principles and practice of oncology, 5th edn. Philadelphia, PA: Lippincott-Raven, 1997:333-47.
11. Sobin LH, Wittekind Ch, eds. TNM classification of malignant tumours, 6th edn. Geneva, Switzerland: International Union Against Cancer, 2002.
12. Hosmer DW, Lemeshow S. Applied logistic regression, 2nd edn. New York: Wiley Intersciences, 2000.
13. Fisher LD, Van Belle G. Biostatistics: a methodology for the health sciences, 2nd edn. New York: Wiley Intersciences, 1993.
14. Ozol FR. Ovarian cancer. In: Steele GD, Phillips TL, Chabner BA, eds. Atlas of clinical oncology. Hamilton, Ontario, Canada: BC Decker Inc., 2003.
15. Herzog TJ, Holloway RW, Stuart GCE. Workshop: options for therapy in ovarian cancer. Gynecol Oncol 2003;90:545-50.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1995;1:27-31.
17. Abulafia O, Ruiz JE, Holcomb K et al. Angiogenesis in early-invasive and low-malignant-potential epithelial ovarian carcinoma. Obstet Gynecol 2000;95:548-52.
18. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Am J Pathol 1995;147:33-41.
19. Kohn EC. Angiogenesis in ovarian carcinoma. Cancer 1997;80:2219-21.
20. Miller KD, Sweeney CJ, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195-206.
21. Belotti D, Vergani V, Drudis T et al. The microtubuli-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
22. Taraboletti G, Micheletti G, Rieppi M et al. Anti-angiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 2002;8:1182-8.
23. Copeland LJ, Bookman M, Trimble E. Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5. Gynecol Oncol 2003;90:S1-7.
24. Stuart GCE. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 2003;90:S8-15.